Breaking News
Get 40% Off 0
🤯 Perficient is up a mind-blowing 53%. Our ProPicks AI saw the buying opportunity in March. Read full update
Close

Lipocine Inc (LPCN)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Lipocine's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
4.9200 +0.2400    +5.13%
21:00:59 - Closed. Currency in USD ( Disclaimer )
After Hours
5.0100
+0.0900
+1.8293%
21:04:07 - Real-time Data
  • Volume: 23,088
  • Bid/Ask: 0.0000 / 0.0000
  • Day's Range: 4.6900 - 5.1100
Type:  Equity
Market:  United States
Lipocine 4.9200 +0.2400 +5.13%

Lipocine Company Profile

 
Read the Lipocine Inc company profile to learn more about the business and the management team. View Lipocine Inc facts about employee data, company products and services, and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

17

Equity Type

ORD

Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company’s pipeline candidates also include TLANDO XR a candidate for oral TRT for once daily dosing, which has completed Phase 2b clinical study; LPCN 1148, an oral prodrug of bioidentical testosterone, being developed for the treatment of cirrhosis, currently under Phase 2 clinical studies; LPCN 1154, An oral neurosteroid, being developed for the treatment of postpartum depression, currently under Phase 2 studies; LPCN 2101, a NAS candidate, for women with epilepsy; and LPCN 2203 for essential tremor. It is also involved in the development of LPCN 1144, an oral prodrug of bioidentical testosterone for the treatment of pre-cirrhotic non-alcoholic steatohepatitis, which has completed Phase 2 testing; and LPCN 1107, an oral product candidate of 17-alpha-hydroxy progesterone caproate product, currently under Phase 3 studies for the prevention of recurrent preterm birth. The company was founded in 1997 and is headquartered in Salt Lake City, Utah.

Contact Information

Address 675 Arapeen Drive Suite 202
Salt Lake City, 84108
United States
Phone 801 994 7383
Fax 801 994 7388

Top Executives

Name Age Since Title
Jill M. Jene 49 2022 Independent Director
Mahesh V. Patel 65 1997 Co-Founder, Interim Principal Financial Officer, Director, President & CEO
Rex P. Hjelm - - Member of Scientific Advisory Board
William N. Charman 63 - Member of Scientific Advisory Board
Richard Dana Ono 70 2014 Independent Director
Alan F. Hofmann - - Member of Scientific Advisory Board
George Zografi - - Member of Scientific Advisory Board
Leslie Z. Benet 85 - Member of Scientific Advisory Board
Tsuneji Nagai - - Member of Scientific Advisory Board
John W. Higuchi 55 2003 Director
Bradley D. Anderson - - Member of Scientific Advisory Board
Ronald T. Borchardt - - Member of Scientific Advisory Board
Norman Ho - - Member of Scientific Advisory Board
Jeffrey Arvin Fink 65 2014 Independent Director
Spyridon Papapetropoulos 51 2022 Lead Independent Director & Chairman of the Board
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

LPCN Price Commentary

Write your thoughts about Lipocine Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
francesco rinaldi
francesco rinaldi Aug 11, 2022 15:32
Saved. See Saved Items.
This comment has already been saved in your Saved Items
What the heck. Pre market + 22% then nothing. No way
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email